OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection.
Twelve pediatric patients, aged 28 months to 17 years, received OKT3 to reverse renal allograft rejection. In 11 patients, the rejection crisis was resistant to conventional antirejection therapy with high doses of prednisone or polyclonal antithymocyte globulin. Reversal of rejection was successful in 10 patients who completed a treatment course. Because of recurring resistant rejection, five patients received a second course of OKT3, which was successful in reversing the rejection crisis in two. Among these patients, the persistence or the appearance of high levels of circulating T3 lymphocytes after initiating the second treatment course correlated with treatment failure. The immediate side effects associated with OKT3 therapy were transient and medically manageable. We conclude that this monoclonal antibody preparation is a safe and effective treatment for pediatric renal allograft in recipients experiencing rejection crisis resistant to conventional therapy. However, the potential impact of this immunosuppressive medication on long-term renal allograft survival in this patient population remains to be determined.
Leone
M R
MR
Alexander
S R
SR
Barry
J M
JM
Henell
K
K
Funnell
M B
MB
Goldstein
G
G
Norman
D J
DJ
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D006084:Graft Rejection; D006801:Humans; D007108:Immune Tolerance; D007668:Kidney / Q000276:immunology; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology*; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface